In another round of corporate musical chairs, diagnostics giant Hologic ($HOLX) implemented a series of leadership changes designed to give it a much-needed boost.<br /><br />The company appointed Eric Compton, the former worldwide president of Ortho Clinical Diagnostics at Johnson & Johnson ($JNJ), as its chief operating officer--a newly established role. Claus Egstrand was named senior vice president and general manager, and will be responsible for overseeing the company's operations outside of the U.S. Egstrand previously worked in senior positions at pharma and medical device companies such as Stryker ($SYK), Merck ($MRK) and Pfizer ($PFE). David Harding, Hologic's former general manager of women's health, was named as senior vice president of corporate strategy.<br /><br />Hologic also said goodbye to Chief Financial Officer Glenn Muir, who retired after 25 years with the company.<br /><br />Read more: Hologic adds a COO, loses a CFO in a C-level shakeup - FierceMedicalDevices <br /><br />"I am excited about the changes announced today and am confident this new executive leadership structure will help accelerate organic growth in each of our businesses on a global basis, improve our operational and financial performance, and continue innovating to deliver the best solutions for our customers," CEO Stephen MacMillan said in a statement. MacMillan is the former CEO of Stryker. "As I have done through the years, I love building winning teams. Both Eric and Claus have demonstrated track records of success and are the right leaders to help take our performance to the next level."<br /><br />The corporate shakeup is all a part of investor Carl Icahn's plan to turn the underperforming company around. Icahn grabbed a 12.6% stake in Hologic in 2013, and gained enough leverage to start making strategic changes. The company adopted a poison pill plan to fend off share-based takeovers, and rumors began circulating about potential M&A.<br /><br />Since then, Hologic has made key organizational changes intended to set itself back on track track: In December 2013, the company threw out Jack Cumming as CEO and replaced him with MacMillan. Hologic also added two top-level executives from Icahn Capital, a subsidiary of Icahn Enterprises. The changes in management were intended to increase the company's "shareholder value," Hologic said in an earlier statement.<br /><br />While future M&A plans remain unclear, the company continues to revamp its identity. After absorbing diagnostics rival Gen-Probe in a $3.8 billion buyout in 2012, profits dipped and Hologic began to rethink strategy. New management changes could be just what the company needs to increase revenue--and attract the eye of potential investors.